MS vs PFE: Which Is the Better Buy?
Side-by-side comparison of Morgan Stanley and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Morgan Stanley · Financial Services
$218.37
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
MS has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MS |
PFE |
| Current Price |
$218.37 |
$25.22 |
| Fair Value Estimate |
$316.64 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$344.4B |
$143.7B |
| Forward P/E |
23.6x
|
19.2x
|
| EV / EBITDA |
9.8x
|
12.3x
|
| Price / Sales |
2.7x
|
2.3x
|
| Price / FCF |
-327.4x
|
15.2x
|
| Revenue Growth YoY |
+22.4%
|
+5.4%
|
| Gross Margin |
56.6%
|
69.3%
|
| Operating Margin |
28.4%
|
23.4%
|
| Return on Equity |
23.4%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
6.6%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Morgan Stanley is a leading global financial services firm specializing in capital markets, wealth management, and investment banking. The company demonstrates high business quality with a strong return on equity of 23.4% and robust revenue growth of 22.4% in the most recent quarter, alongside impressive earnings growth of 57.7% in the same period. Its gross margin of 56.6% and net margin of 20.2…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
MS |
PFE |
| Zone Low |
$237.48 |
$19.44 |
| Zone High |
$269.14 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|